PHAXIAM Therapeutics SA

Monthly information related to total number of voting rights and shares composing the share capital - January 31, 2024

06 2月 2024 16:05:00 条件 Nasdaq GlobeNewswire

PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

18 1月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital - December 31, 2023

03 1月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital - November 30, 2023

06 12月 2023 16:05:00 条件 Nasdaq GlobeNewswire

PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

14 11月 2023 16:05:00 条件 Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023

07 11月 2023 12:00:00 条件 Nasdaq GlobeNewswire

PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

24 10月 2023 16:05:00 条件 Nasdaq GlobeNewswire

TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation

23 10月 2023 16:05:00 条件 Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2023

23 10月 2023 12:00:00 条件 Nasdaq GlobeNewswire